This subtype characterises 40–70% of ovarian cancers and renders a chemoresistant phenotype that is more difficult to overcome than that in p53 wild-type (wt) tumours (Lavarino et al, 2000; Canevari et al, 2006). This evidence concerns the gene TP53 and ovarian cancer.